Josh Kaufman

• U.S. counsel to Danish biotech on $1.0 billion equity capital raise through leading global investment banks
• U.S. counsel to Swedish biopharma on $1.1 billion friendly cash tender offer from Japanese conglomerate
• Advised underwriting syndicates in the first dual listings of Danish and Swedish companies in the United States
• Advised a New York biotech in its US$40 million IPO and numerous follow-on offerings
• Advised an underwriting syndicate on a UK pharmaceutical company's US$380 million IPO
• Advised a national restaurant chain in its US$140 million primary offering and US$75 million at-the-market (ATM) offering
• Advised the sales agents on a $1.0 billion ATM for an agency residential mortgage REIT
• Advised a UK-listed biotech in its transition to Nasdaq and numerous follow-on offerings
• Advised on four technology and healthcare IPOs out of Israel aggregating US$1.2 billion
• Advised a national shopping center REIT on a $950 million IPO

Before joining DLA Piper, Mr. Kaufman served as partner at one AmLaw 100 law firm and prior to that as counsel at another AmLaw 100 law firm. He previously worked as an investment banker at Lehman Brothers, focused on corporate financings and leveraged buyouts.